ALZpath Signs Global Licensing Agreement with Abbott Laboratories for Alzheimer's Blood Test Development

On June 24, 2026, ALZpath and Abbott Laboratories entered into a global licensing agreement. The partnership focuses on the development of a blood test for Alzheimer's disease. This agreement represents a collaboration between ALZpath and Abbott Laboratories to advance diagnostic tools for Alzheimer's disease globally, aiming to improve detection and diagnostic options.

ALZpath-Abbott licensing agreement

• ▪ALZpath signed a licensing agreement with Abbott Laboratories to develop an Alzheimer's blood test on or before June 24, 2026
• ▪The licensing agreement signed between ALZpath and Abbott Laboratories is global in scope